Tirzepatide Associated with Lower Risk of Heart and Kidney Damage Compared to Dulaglutide in Patients with Type 2 Diabetes and Cardiovascular Disease
A Cleveland Clinic analysis has found that tirzepatide, a medication that activates both GLP‑1 and GIP hormone receptors,…